Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
$30 million financing secured to pursue brachytherapy breast cancer treatment
June 6th, 2005
Xoft, Inc., a company developing electronic brachytherapy for cancer treatment, has closed a commercialization round of financing, raising $30 million. Demonstrating continued support for the proprietary, technology designed to deliver nonradioactive, isotope-free radiation treatment in virtually any clinical setting, the investment will allow Xoft to complete clinical validation studies on the Axxent Electronic Brachytherapy system and launch it in the multi-billion dollar breast cancer therapeutics market. The Axxent Electronic Brachytherapy System, pending clearance from the U.S. Food and Drug Administration (FDA), uses disposable micro-miniature...
Source: Biotech Business Week (2005-06-06)
|
